Showing 2061-2070 of 5839 results for "".
- Study: Female Adult Acne Patients Face Stigmahttps://practicaldermatology.com/news/study-female-adult-acne-patients-face-stigma/2462073/Faces with acne are seen as less attractive, trustworthy, confident, successful, dominant and happy, and adult female acne has the strongest negative effect, according to research presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. The
- Roflumilast Foam 0.3% Eases Scalp Itch in as Early as 24 hourshttps://practicaldermatology.com/news/roflumilast-foam-03-eases-scalp-itch-in-as-early-as-24-hours/2462068/Arcutis’ roflumilast foam 0.3% demonstrated significant improvements in both scalp and body psoriasis across all efficacy endpoints when compared to vehicle, according to patient-reported outcome data from the pivotal ARRECTOR Phase 3 trial in scalp and body psoriasis presented at the
- EADV News: Almirall’s Ilumetri Improves Well-being of Pso Patients and Their Familieshttps://practicaldermatology.com/news/eadv-news-almiralls-ilumetri-improves-well-being-of-pso-patients-and-their-families/2462056/Ilumetri (tildrakizumab) significantly improves the well-being of psoriasis patients and their relatives, according to new data presented at the European Association of Dermatology and Venereology Congress 2023. Interim data from the POSITIVE study showed that tildrakizumab significantl
- FDA Approves Novartis Cosentyx as First IV Formulation IL-17A Antagonist for PsAhttps://practicaldermatology.com/news/fda-approves-novartis-cosentyx-as-first-iv-formulation-il-17a-antagonist-for-psa/2462048/The US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Novartis’ Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Cosentyx
- Antibiotic-induced Acute Generalized Exanthematous Pustulosis: A Case Study of an 18-year-old Pregnant Female Presenting with Fever, Tachycardia, and Pustular Skin Eruptionhttps://practicaldermatology.com/news/antibiotic-induced-acute-generalized-exanthematous-pustulosis-a-case-study-of-an-18-year-old-pregnant-female-presenting-with-fever-tachycardia-and-pustular-skin-eruption/2462046/On the day of giving birth via vaginal delivery complicated by intrauterine fetal demise, an 18-year-old female, G1P000, developed preeclampsia with severe features. The patient subsequently developed chorioamnionitis and was started on ampicillin-gentamicin. After administration of the antibioti
- FDA Approves Arcutis’ ZORYVE (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11https://practicaldermatology.com/news/fda-approves-arcutis-zoryve-roflumilast-cream-03-for-treatment-of-psoriasis-in-children-ages-6-to-11/2462045/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis, including intertriginous areas, to children ages 6 to 11 years. “T
- Regenerative Medicine Breakthrough: Researchers Create BioPrinted Full Thickness Skinhttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-researchers-create-bioprinted-full-thickness-skin/2462041/New bioprinted skin may accelerate wound healing, support healthy extracellular matrix remodeling, and aid in complete wound recovery, according to research out of the Wake Forest Institute for Regenerative Medicine (WFIRM). Available grafts are often temporary, or if permanent, h
- AD Pipeline Update: FDA Rejects Lilly’s Lebrikizumab Due to Third-Party Manufacturing Issueshttps://practicaldermatology.com/news/ad-pipeline-update-fda-rejects-lillys-lebrikizumab-due-to-third-party-manufacturing-issues/2462037/The U.S. Food and Drug Administration (FDA) did not approve Eli Lilly's lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis due to findings during an inspection of a contract manufacturer. The letter cited findings
- Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201https://practicaldermatology.com/news/cabaletta-bio-receives-fda-clearance-of-ind-application-for-treatment-of-systemic-sclerosis-with-caba-201/2462036/The U.S. Food and Drug Administration (FDA) is allowing Cabaletta Bio, Inc.’s third Investigational New Drug (IND) application for CABA-201 to proceed. for a Phase 1/2 study in patients with systemic sclerosis (SSc). CABA-201 is a 4-1BB-containing fully human CD19-CAR T cell
- FDA Approves Merz Aesthetics’ Belotero Balance (+) for Infraorbital Hollowshttps://practicaldermatology.com/news/fda-approves-merz-aesthetics-belotero-balance-for-infraorbital-hollows/2462028/The U.S. Food and Drug Administration (FDA) approved Merz Aesthetics’ Belotero Balance (+) for improvement of the infraorbital hollow (IOH) in adults over the age of 21. This approval stems from positive pivotal study results demonstrating the efficacy and safety o